PM8002

PM8002 (BNT327) is a bispecific antibody developed by Biotheus. Its targets are PD-L1 and VEGF / VEGFR (the sponsor names PD-L1 x VEGF). The sponsor states: Study brief summary states PM8002 is a bispecific antibody targeting PD-L1 and VEGF; no further mechanistic detail given. ClinicalTrials.gov describes the intervention as: PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06616532 (PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer) and NCT06419621 (PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC), in small-cell lung cancer, triple-negative breast cancer, neuroendocrine tumours, colorectal cancer and non-small-cell lung cancer. The largest, NCT06616532, plans to enrol 404 participants with primary completion expected 2027-01-25. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.